In this prospective pilot study, researchers investigated the safety and efficacy of topical treatment with 5FU in this group of patients.
The study included 46 men with grade 1-3 anal intraepithelial neoplasia who were treated with 5FU twice weekly for 16 weeks. Patients were followed up after 6 months.
A total of 18 patients had a complete response, 8 had a partial response and 17 did not respond to treatment. After 6 months, 50% of complete responders experienced recurrence.
The authors conclude that a substantial proportion of HIV-positive men with anal intraepithelial neoplasia respond to treatment with topical 5FU.
Richel O, Wieland U, de Vries HJC et al. Br J Dermatol 2010; 163: 1301-7